Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Nocebo Effect in Dermatology Publisher Pubmed



Sonthalia S1 ; Sahaya K2 ; Arora R3 ; Singal A3 ; Srivastava A4 ; Wadhawan R5 ; Zartab H6 ; Gupta K7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skinnocence: the Skin Clinic, C-2246, Sushant Lok-1, Gurgaon, India
  2. 2. University of Arkansas for Medical Sciences, Little Rock, AR, United States
  3. 3. Department of Dermatology and STD, UCMS and GTB Hospital, Delhi, India
  4. 4. Department of Psychiatry, Westmead Hospital, Sydney, NSW, Australia
  5. 5. Bhim Rao Ambedkar College (University of Delhi), Delhi, India
  6. 6. Center for Research and Training in Skin Diseases and Leprosy (CRTSDL), Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Medic Affairs, Eli Lilly India Pvt Ltd., Gurgaon, India

Source: Indian Journal of Dermatology# Venereology and Leprology Published:2015


Abstract

Nocebo effect, originally denoting the negative counterpart of the placebo phenomenon, is now better defined as the occurrence of adverse effects to a therapeutic intervention because the patient expects them to develop. More commonly encountered in patients with a past negative experience, this effect stems from highly active processes in the central nervous system, mediated by specific neurotransmitters and modulated by psychological mechanisms such as expectation and conditioning. The magnitude of nocebo effect in clinical medicine is being increasingly appreciated and its relevance encompasses clinical trials as well as clinical practice. Although there is hardly any reference to the term nocebo in dermatology articles, the phenomenon is encountered routinely by dermatologists. Dermatology patients are more susceptible to nocebo responses owing to the psychological concern from visibility of skin lesions and the chronicity, unpredictable course, lack of 'permanent cure' and frequent relapses of skin disorders. While finasteride remains the prototypical drug that displays a prominent nocebo effect in dermatologic therapeutics, other drugs such as isotretinoin are also likely inducers. This peculiar phenomenon has recently been appreciated in the modulation of itch perception and in controlled drug provocation tests in patients with a history of adverse drug reactions. Considering the conflict between patients' right to information about treatment related adverse effects and the likelihood of nocebo effect stemming from information disclosure, the prospect of ethically minimizing nocebo effect remains daunting. In this article, we review the concept of nocebo effect, its postulated mechanism, relevance in clinical dermatology and techniques to prevent it from becoming a barrier to effective patient management.